CPX‐351 (Vyxeos ® ) can cause severe rash in acute myeloid leukemia—A case report-Reference-Cited by-同舟云学术

CPX‐351 (Vyxeos ® ) can cause severe rash in acute myeloid leukemia—A case report

Published:2021-02-12 Issue:4 Volume:9 Page:1933-1936
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clin Case Rep

Author:

Urbantat Ruth M.¹²³⁴,Popper Valentin¹²,Menschel Elisabeth¹,Pfeilstöcker Michael¹,Forjan Ernst¹,Nader Alexander¹^ORCID,Sieghart Catherine R.¹,Keil Felix¹,Koller Elisabeth¹^ORCID

Affiliation:

1. OeGK‐Hanusch Krankenhaus Vienna Austria

2. Medizinische Universität Vienna Austria

3. Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin Humboldt‐Universität zu Berlin Berlin Germany

4. Berlin Institute of Health Berlin Germany

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.3909

Reference29 articles.

1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

2. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study

3. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

4. European Medicines Agency.Vyxeos INN‐Daunorubicin / Cytarabine.2018.https://www.ema.europa.eu/en/documents/assessment‐report/vyxeos‐epar‐public‐assessment‐report_en.pdf. Accessed June 28 2018.

5. FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dermatologic complications in transplantation and cellular therapy for acute leukemia;Best Practice & Research Clinical Haematology;2023-06

2. CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML;Cancers;2022-06-08

3. Cytarabine/daunorubicin;Reactions Weekly;2021-06